Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
125.63
-1.58 (-1.25%)
Mar 25, 2025, 4:00 PM EST - Market closed
Abbott Laboratories Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 41,950 | 40,109 | 43,653 | 43,075 | 34,608 | Upgrade
|
| Revenue Growth (YoY) | 4.59% | -8.12% | 1.34% | 24.46% | 8.48% | Upgrade
|
| Cost of Revenue | 18,644 | 17,919 | 19,083 | 18,080 | 15,003 | Upgrade
|
| Gross Profit | 23,306 | 22,190 | 24,570 | 24,995 | 19,605 | Upgrade
|
| Selling, General & Admin | 11,109 | 10,385 | 10,703 | 11,006 | 9,591 | Upgrade
|
| Research & Development | 2,823 | 2,619 | 2,741 | 2,738 | 2,420 | Upgrade
|
| Operating Expenses | 15,810 | 14,970 | 15,457 | 15,791 | 14,143 | Upgrade
|
| Operating Income | 7,496 | 7,220 | 9,113 | 9,204 | 5,462 | Upgrade
|
| Interest Expense | -559 | -637 | -558 | -533 | -546 | Upgrade
|
| Interest & Investment Income | 344 | 385 | 183 | 43 | 46 | Upgrade
|
| Currency Exchange Gain (Loss) | 27 | -41 | -2 | -1 | 8 | Upgrade
|
| Other Non Operating Income (Expenses) | -166 | -22 | -85 | 7 | 13 | Upgrade
|
| EBT Excluding Unusual Items | 7,142 | 6,905 | 8,651 | 8,720 | 4,983 | Upgrade
|
| Merger & Restructuring Charges | -129 | -144 | -234 | -509 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -39 | - | - | -115 | Upgrade
|
| Asset Writedown | - | -100 | -111 | - | - | Upgrade
|
| Legal Settlements | - | - | - | - | 100 | Upgrade
|
| Other Unusual Items | - | 42 | - | - | - | Upgrade
|
| Pretax Income | 7,013 | 6,664 | 8,306 | 8,211 | 4,968 | Upgrade
|
| Income Tax Expense | -6,389 | 941 | 1,373 | 1,140 | 497 | Upgrade
|
| Earnings From Continuing Operations | 13,402 | 5,723 | 6,933 | 7,071 | 4,471 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | 24 | Upgrade
|
| Net Income | 13,402 | 5,723 | 6,933 | 7,071 | 4,495 | Upgrade
|
| Preferred Dividends & Other Adjustments | 51 | 22 | 28 | 29 | 22 | Upgrade
|
| Net Income to Common | 13,351 | 5,701 | 6,905 | 7,042 | 4,473 | Upgrade
|
| Net Income Growth | 134.18% | -17.45% | -1.95% | 57.31% | 21.92% | Upgrade
|
| Shares Outstanding (Basic) | 1,740 | 1,740 | 1,753 | 1,775 | 1,773 | Upgrade
|
| Shares Outstanding (Diluted) | 1,748 | 1,749 | 1,764 | 1,789 | 1,786 | Upgrade
|
| Shares Change (YoY) | -0.06% | -0.85% | -1.40% | 0.17% | 0.28% | Upgrade
|
| EPS (Basic) | 7.67 | 3.28 | 3.94 | 3.97 | 2.52 | Upgrade
|
| EPS (Diluted) | 7.64 | 3.26 | 3.91 | 3.94 | 2.50 | Upgrade
|
| EPS Growth | 134.36% | -16.62% | -0.76% | 57.38% | 21.53% | Upgrade
|
| Free Cash Flow | 6,351 | 5,059 | 7,804 | 8,648 | 5,724 | Upgrade
|
| Free Cash Flow Per Share | 3.63 | 2.89 | 4.42 | 4.83 | 3.21 | Upgrade
|
| Dividend Per Share | 2.240 | 2.080 | 1.920 | 1.820 | 1.530 | Upgrade
|
| Dividend Growth | 7.69% | 8.33% | 5.50% | 18.95% | 15.91% | Upgrade
|
| Gross Margin | 55.56% | 55.32% | 56.28% | 58.03% | 56.65% | Upgrade
|
| Operating Margin | 17.87% | 18.00% | 20.88% | 21.37% | 15.78% | Upgrade
|
| Profit Margin | 31.83% | 14.21% | 15.82% | 16.35% | 12.93% | Upgrade
|
| Free Cash Flow Margin | 15.14% | 12.61% | 17.88% | 20.08% | 16.54% | Upgrade
|
| EBITDA | 10,714 | 10,463 | 12,380 | 12,742 | 8,789 | Upgrade
|
| EBITDA Margin | 25.54% | 26.09% | 28.36% | 29.58% | 25.40% | Upgrade
|
| D&A For EBITDA | 3,218 | 3,243 | 3,267 | 3,538 | 3,327 | Upgrade
|
| EBIT | 7,496 | 7,220 | 9,113 | 9,204 | 5,462 | Upgrade
|
| EBIT Margin | 17.87% | 18.00% | 20.88% | 21.37% | 15.78% | Upgrade
|
| Effective Tax Rate | - | 14.12% | 16.53% | 13.88% | 10.00% | Upgrade
|
Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.